Press Releases

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. "Dosing of the first patient in Part 2 of this trial, late in

Kane Biotech Inc., announces that it has entered into a worldwide license agreement with I-MED Pharma Inc.,for the DispersinB® technology. Biofilm is a known contributor to Meibomian gland dysfunction (MGD) and dry eye blepharitis syndrome (DEBS). The DispersinB® enzyme will be used to enhance I-MED’s line of eye care products. The license agreement covers a period of five years and includes minimum annual royalties, which will start in 2025. “This agre

Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD). WVE-003 is a first-in-class, allele-selective antisense oligonucleotide (ASO) designed to lower mutant huntingtin (mHTT) protein and preserve healthy,

Harmony Biosciences today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy. The FDA separated the submission into two sNDAs for administrative purposes to issue an approval for the treatment of EDS and a complete response for the treatment of cataplexy in pediatric patients

CatSci Ltd, an award-winning innovation partner for medicines development, announces the acquisition of Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics. The acquisition was supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth Buyout[1] investments. Headquartered in the United Kingdom, and with laboratories in both the UK and France, Reach Separat

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a definitive agreement with ProGen Co., Ltd., a South Korean clinical-stage biotech company developing next generation long-acting, multi-specific fusion protein therapeutics, for the co-development and commercialization of RT-114, an oral RaniPill® capsule containing ProGen’s PG-102, a GLP-1/GLP-2 dual agonist, for

Bristol Myers Squibb today announced that the European Medicines Agency has validated the extension application to introduce a new route of administration for Opdivo® that includes a new pharmaceutical form (solution for injection) and a new strength (600 mg/vial) across multiple previously approved adult solid tumor indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab combination therapy, or in combination with chemotherapy or cabozantinib

Starton Therapeutics Inc., a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today positive interim top-line data from its low-dose lenalidomide STAR-LLD Phase 1b clinical trial in multiple myeloma (MM). The study, designed to assess the safety, pharmacokinetics, and efficacy of the Company’s STAR-LLD in combination with dexamethasone and bortezomib (Velcade®), met the primary objective of safety and tolera

Palisade Bio, Inc., a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an update on key areas of progress for its previously announced strategic collaboration with Strand Life Sciences ("Strand"), a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy. Under the collaboration through an extensive an

Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced the initiation of a Phase 1b study evaluating NMRA-511 for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD). NMRA-511 is an oral, highly potent and selective antagonist of the vasopressin 1a receptor (V1aR) and is highly brain penetrant. Modulation of the V1aR